PE20211280A1 - Sales cristalinas de un inhibidor de calicreina plasmatica - Google Patents
Sales cristalinas de un inhibidor de calicreina plasmaticaInfo
- Publication number
- PE20211280A1 PE20211280A1 PE2021000587A PE2021000587A PE20211280A1 PE 20211280 A1 PE20211280 A1 PE 20211280A1 PE 2021000587 A PE2021000587 A PE 2021000587A PE 2021000587 A PE2021000587 A PE 2021000587A PE 20211280 A1 PE20211280 A1 PE 20211280A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydrogen
- plasmatic
- crystalline salts
- delivery system
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Referido a un sistema de administracion de farmacos que comprende D-R, que esta representado por la Formula (I), donde D es un resto biologicamente activo que comprende al menos una amina primaria o secundaria o un atomo de nitrogeno anular de un anillo de azaheteroarilo; y R es un ligante adecuado para la liberacion del resto biologicamente activo D; R1 es hidrogeno o C1-C4 alquilo; R1a es hidrogeno o C1-C4 alquilo, entre otros; R2 se selecciona independientemente entre C1-C4 alquilo o oxo, entre otros; a es 0, 1, 2, 3 o 4; R3 es hidrogeno o C1-C4 alquilo; R3a es hidrogeno, C1-C4 alquilo, entre otros; Y es C(O)R4, C(O)OR4, entre otros; y Z es CH-L-A, CH-A, N-L-A o N-A, donde L es un enlazador bivalente opcionalmente sustituido; A es hidrogeno, C1-C8 alquilo, entre otros. Tambien se refiere a un portador que se conjuga al farmaco a traves del ligante estable. Dicho sistema de administracion es util para el tratamiento de trastornos musculoesqueleticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754983P | 2018-11-02 | 2018-11-02 | |
| PCT/US2019/059385 WO2020092898A1 (en) | 2018-11-02 | 2019-11-01 | Crystalline salts of a plasma kallikrein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211280A1 true PE20211280A1 (es) | 2021-07-19 |
Family
ID=70457981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000587A PE20211280A1 (es) | 2018-11-02 | 2019-11-01 | Sales cristalinas de un inhibidor de calicreina plasmatica |
Country Status (21)
| Country | Link |
|---|---|
| US (10) | US10662160B1 (es) |
| EP (1) | EP3873463A4 (es) |
| JP (2) | JP2022505670A (es) |
| KR (1) | KR102810837B1 (es) |
| CN (1) | CN112969458A (es) |
| AR (1) | AR116951A1 (es) |
| AU (1) | AU2019374115B8 (es) |
| BR (1) | BR112021008249A2 (es) |
| CA (1) | CA3117123A1 (es) |
| CL (1) | CL2021001094A1 (es) |
| CO (1) | CO2021007172A2 (es) |
| EA (1) | EA202191192A1 (es) |
| IL (2) | IL322896A (es) |
| MA (1) | MA54087A (es) |
| MX (1) | MX2021004917A (es) |
| PE (1) | PE20211280A1 (es) |
| PH (1) | PH12021550883A1 (es) |
| SG (1) | SG11202103804TA (es) |
| TW (1) | TW202031255A (es) |
| UY (1) | UY38438A (es) |
| WO (1) | WO2020092898A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100031T1 (it) | 2014-03-07 | 2021-03-15 | Biocryst Pharm Inc | Pirazoli trifluorometil-sostituiti come inibitori della callicreina plasmatica umana |
| AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| WO2021025969A1 (en) * | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| EP1828187A2 (en) | 2004-12-15 | 2007-09-05 | Brystol-Myers Squibb Company | Crystalline forms of a factor xa inhibitor |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CA2798010C (en) | 2010-05-19 | 2018-09-25 | Sandoz Ag | Purification of posaconazole and of posaconazole intermediates |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| SMT202100031T1 (it) | 2014-03-07 | 2021-03-15 | Biocryst Pharm Inc | Pirazoli trifluorometil-sostituiti come inibitori della callicreina plasmatica umana |
| LT3355890T (lt) | 2015-10-01 | 2021-12-27 | Biocryst Pharmaceuticals, Inc. | Žmogaus plazmos kalikreino inhibitoriai |
| AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| TWI881995B (zh) | 2019-08-06 | 2025-05-01 | 美商百歐克斯製藥公司 | 血漿激肽釋放酶抑制劑之工業合成 |
-
2019
- 2019-10-31 AR ARP190103187A patent/AR116951A1/es unknown
- 2019-10-31 UY UY0001038438A patent/UY38438A/es unknown
- 2019-11-01 WO PCT/US2019/059385 patent/WO2020092898A1/en not_active Ceased
- 2019-11-01 MA MA054087A patent/MA54087A/fr unknown
- 2019-11-01 SG SG11202103804TA patent/SG11202103804TA/en unknown
- 2019-11-01 BR BR112021008249-2A patent/BR112021008249A2/pt unknown
- 2019-11-01 US US16/671,649 patent/US10662160B1/en active Active
- 2019-11-01 PE PE2021000587A patent/PE20211280A1/es unknown
- 2019-11-01 CN CN201980072995.3A patent/CN112969458A/zh active Pending
- 2019-11-01 MX MX2021004917A patent/MX2021004917A/es unknown
- 2019-11-01 TW TW108139655A patent/TW202031255A/zh unknown
- 2019-11-01 IL IL322896A patent/IL322896A/en unknown
- 2019-11-01 CA CA3117123A patent/CA3117123A1/en active Pending
- 2019-11-01 KR KR1020217013734A patent/KR102810837B1/ko active Active
- 2019-11-01 EA EA202191192A patent/EA202191192A1/ru unknown
- 2019-11-01 EP EP19877809.4A patent/EP3873463A4/en active Pending
- 2019-11-01 AU AU2019374115A patent/AU2019374115B8/en active Active
- 2019-11-01 JP JP2021522086A patent/JP2022505670A/ja active Pending
-
2020
- 2020-02-06 US US16/784,016 patent/US11117867B2/en active Active
-
2021
- 2021-04-20 IL IL282454A patent/IL282454A/en unknown
- 2021-04-21 PH PH12021550883A patent/PH12021550883A1/en unknown
- 2021-04-27 CL CL2021001094A patent/CL2021001094A1/es unknown
- 2021-05-31 CO CONC2021/0007172A patent/CO2021007172A2/es unknown
- 2021-09-02 US US17/465,181 patent/US11618733B2/en active Active
-
2023
- 2023-03-10 US US18/120,073 patent/US12344585B2/en active Active
-
2024
- 2024-05-27 JP JP2024085295A patent/JP2024109860A/ja active Pending
-
2025
- 2025-05-30 US US19/224,669 patent/US20250388545A1/en active Pending
- 2025-08-28 US US19/312,645 patent/US12545645B2/en active Active
- 2025-08-28 US US19/312,786 patent/US12545647B2/en active Active
- 2025-08-28 US US19/312,755 patent/US12545646B2/en active Active
- 2025-08-28 US US19/313,046 patent/US20250376448A1/en active Pending
- 2025-08-28 US US19/313,010 patent/US20250388549A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191837A1 (es) | Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas | |
| PE20211280A1 (es) | Sales cristalinas de un inhibidor de calicreina plasmatica | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| HN2012001037A (es) | Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| AR049647A1 (es) | Cis-imidazolinas | |
| PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| CO6270307A2 (es) | Derivados bis-(sulfonilamino) en terapia | |
| CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| PE20211646A1 (es) | Administracion sostenida de polipeptidos similares a la angiopoyetina 3 | |
| AR061419A1 (es) | Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3 | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| CY1111102T1 (el) | 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| CL2019000727A1 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. | |
| DOP2023000205A (es) | Nuevos moduladores de nr2b alostéricos negativos de ciclopenta[c]pirrol | |
| PE20040943A1 (es) | 2-AMINOIMIDAZOLES SUSTITUIDOS COMO INHIBIDORES DEL INTERCAMBIADOR Na/H SUBTIPO 3 (NHE 3) | |
| AR085822A1 (es) | Moduladores alostericos positivos del receptor nicotinico de acetilcolina | |
| UY39722A (es) | Nuevos derivados de heteroaril aminopropanol |